Full-Time

Senior Director

Cardiovascular

Posted on 9/9/2026

Varian

Varian

5,001-10,000 employees

Tech-enabled radiation oncology hardware and software

Compensation Overview

$158.3k - $217.7k/yr

+ Commission

Company Historically Provides H1B Sponsorship

Remote in USA

Remote

Bachelor's, Master's, MBA

Category
Business & Strategy (1)

Get referred to Varian

See people who can refer or advise you

Requirements
  • Business leadership experience within a cardiovascular or cardiology service line at a U.S. health system, such as a service line director, administrative dyad partner, Vice President of Cardiology, or equivalent operational leader.
  • At least 10 years of healthcare experience spanning service line operations, strategy, transformation, growth planning, or business development.
  • A proven track record in developing and managing business cases, financial plans, and strategic growth initiatives with clearly defined objectives and expected returns.
  • Experience influencing stakeholders and leading cross-functional teams in a complex, matrixed organization.
  • A master's degree is required.
Responsibilities
  • Partner with Business Line and Business Area teams to identify, develop, and advance short- and long-term strategic initiatives aligned with North America Enterprise Services priorities, emphasizing cardiovascular opportunities where customer needs, patient pathways, and market opportunity intersect.
  • Propose and evaluate business cases for new initiatives, ensuring fit with market needs, customer priorities, and the broader Enterprise Services strategy and portfolio.
  • Work collaboratively with existing Business Line teams on current and future technology innovation, translating those capabilities into differentiated programmatic offerings and sustained customer engagement models.
  • Apply a structured approach to innovation with product, clinical, commercial, and Business Line/Business Area stakeholders to evaluate, prioritize, and pilot integrated offerings that improve customers' clinical, operational, and financial performance.
  • Collaborate with Business Line, Business Area, Program Business Development, and sales teams to support go-to-market approaches for Enterprise Services offerings across health system environments.
  • Help shape the commercial narrative and field enablement tools that allow Enterprise Services sales teams to engage health system leadership.
  • Contribute to commercial planning for new program launches with Business Line/Business Area, Program Business Development, and sales teams.
  • Partner with Program Business Development, sales, and Business Line/Business Area teams to gather market feedback, refine program positioning, and connect innovation priorities to customer-facing strategies that drive differentiation and market share.
  • Collaborate across North American commercial teams on thought leadership, conference strategy, and targeted demand generation efforts.
  • Navigate and collaborate across North America sales leadership, Business Line and Business Area leadership, global Enterprise Services leadership, and the North America executive team to advance cross-business strategies.
  • Serve as a strategic connector across Siemens Healthineers stakeholders and third-party partners to align around patient pathways, shared priorities, and integrated customer value propositions.
  • Engage health system clients as a strategic advisor on Enterprise Services capabilities, program design, and partnership strategy.
  • Lead development of Enterprise Services capabilities, offerings, and program structures aligned with Business Line and Business Area priorities in North America.
  • Lead cross-functional initiatives to align program priorities, improve pipeline visibility, and support shared execution across Enterprise Services, Business Line/Business Area teams, and commercial stakeholders.
  • Partner with Enterprise Services Finance to develop business plans for new program launches and monitor performance against business-case assumptions and targets.
  • Contribute to a culture of strategic rigor, clinical credibility, collaboration, and continuous improvement across cross-functional teams.
Desired Qualifications
  • An MBA, MHA, or clinical advanced degree.
  • Breadth of business leadership within a cardiovascular or cardiology service line at a U.S. health system, including operational, strategic, or programmatic accountability beyond procedural or laboratory management.
  • Familiarity with partnership-based healthcare service models, strategic services offerings, or value-oriented health system partnerships.
  • Direct knowledge of Siemens Healthineers Enterprise Services.
  • A background in healthcare strategy, innovation, or program design, with exposure to digital health, population health, or imaging-enabled care models.
  • A track record of building strategic growth initiatives, market-facing programs, or expansion efforts across multiple clinical or operational domains.
  • Experience structuring strategic partnerships, joint ventures, or alliances with medical technology, healthcare services, or health system partners.
  • A strong understanding of U.S. health system and customer needs, with broader awareness of market dynamics across Canada and Latin America.

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.

PR Newswire
Jul 29th, 2024
Varian Announces Future-Focused, Integrated Microwave Ablation Ecosystem With Intelliblate

PALO ALTO, Calif., July 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announces receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system, intended for ablation of soft tissue. Designed to provide clinicians with greater predictability, precision, and control during their procedures, IntelliBlate serves as the cornerstone of a future-focused, integrated ecosystem for microwave ablation.IntelliBlate produces large, controlled spherical ablation zones for predictable treatment delivery. With the option to utilize a single or dual probes – each with linked or independent controls – IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. Precision and control are amplified by the Ximitry probe, which enables innovative features such as Laser Disk Alignment and intuitive LED indicators.The compact, versatile design and intuitive interface of IntelliBlate delivers a portable and flexible system that reduces barriers for this important treatment method. Modular elements provide the flexibility for clinicians to expand their treatment capabilities to meet changing clinical demands, all while keeping control over operational efficiency throughout the ablation procedure."IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation," says Dr